Latest

Latest AstraZeneca News | Page 2

  • Latest AstraZeneca news stories and updates. What is happening today? All recent AstraZeneca news and developments. Live coverage and timeline of AstraZeneca. All you need to know about AstraZeneca.
Alexion data at 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023) showcase impact of C5 inhibition in NMOSD
AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
AstraZeneca research reveals unique associations between rare changes in genes and plasma proteins that could improve drug discovery with data from over…
Forxiga met primary endpoint in T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed to date
AstraZeneca settles Nexium and Prilosec product liability litigations
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01…
Alexion completes purchase and licence agreement for early-stage rare disease gene therapy portfolio from Pfizer
Enhertu recommended for approval in the EU by CHMP for patients with HER2-mutant advanced non-small cell lung cancer
Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
Enhertu demonstrated strong and durable tumour responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Phase II trial
Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
Datopotamab deruxtecan plus Imfinzi showed promising clinical activity in the first-line advanced non-small cell lung cancer setting in TROPION-Lung04 Phase Ib trial
Update on US regulatory review of Ultomiris in NMOSD
Calquence approved in China for chronic lymphocytic leukaemia
AstraZeneca data at ERS 2023 demonstrate leadership in transforming care across a broad respiratory portfolio of inhaled and biologic medicines
Soliris approved in Japan for paediatric patients with generalised myasthenia gravis (gMG)
Lynparza plus abiraterone approved in Japan for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
AstraZeneca demonstrates scientific leadership with compelling new data at ESC Congress 2023 on the interconnections across chronic diseases
Forxiga approved in China to reduce the risk of cardiovascular death and hospitalisation in adult patients with symptomatic chronic heart failure
Trial for COVID-19 prevention in immune-compromised people set to begin at UniSC
AstraZeneca data at WCLC advance ambition to have an AstraZeneca medicine for more than half of all patients treated for lung cancer by 2030
Connection to culture spurs Uncle Ernies recovery
Alice Springs stroke survivor shares story to help others
The WHO has declared Eris a ‘variant of interest’. How is it different from other Omicron variants?
Davids long road to recovery worth fight
F.A.S.T. thinking helped Greg fight back from stroke
Mater Researcher’s lymphoma studies attract funding boost
Country cardiac rehab help launches in SA-NT
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
AstraZeneca appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D
H1 and Q2 2023 results
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial
Soliris approved in the EU for children and adolescents with refractory generalised myasthenia gravis (gMG)
KIPA potentially predicts chemotherapy response in triple negative breast cancer
Beyfortus approved in the US for the prevention of RSV lower respiratory tract disease in infants
Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
Ludwig Cancer Research study shows tumor monocyte content predicts immunochemotherapy outcomes for esophageal cancer
Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial
Imfinzi plus Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four…
Researchers develop a new approach to scale-up manufacturing of life-saving oligonucleotide therapeutics
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
‘The dirty disease’ – both smokers and non-smokers get lung cancer. They face stigma on top of illness
Xigduo XR approved in China for adults with type-2 diabetes
Soliris recommended for approval in the EU by CHMP for children and adolescents with refractory generalised myasthenia gravis (gMG)
TGA Product Information safety updates 23 June
Shane Jones: World Health Organisation needs reform – not fattening
Real-world evidence highlights the urgent need to act on the growing global burden of chronic kidney disease

© 2024 - The National Tribune Australia